Multiple groups have recently emphasized that SAA is a potential therapeutic target in the treatment of diseases associated with chronic inflammation [12], such as psoriasis [36], COPD [35], kidney involvement in autoinflammatory diseases driven by AA amyloidosis [37], as well as lung cancer metastasis [38]. The gene discussed is SAA2; the disease is chronic obstructive pulmonary disease.